- Home
- TETE vs CMRX Comparison
TETE vs CMRX Comparison
Compare TETE & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TETE
- CMRX
- Stock Information
- Founded
- TETE 2021
- CMRX 2000
- Country
- TETE Malaysia
- CMRX United States
- Employees
- TETE N/A
- CMRX N/A
- Industry
- TETE Blank Checks
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- TETE Finance
- CMRX Health Care
- Exchange
- TETE Nasdaq
- CMRX Nasdaq
- Market Cap
- TETE 73.0M
- CMRX 77.1M
- IPO Year
- TETE 2022
- CMRX 2013
- Fundamental
- Price
- TETE $12.30
- CMRX $2.84
- Analyst Decision
- TETE
- CMRX Strong Buy
- Analyst Count
- TETE 0
- CMRX 2
- Target Price
- TETE N/A
- CMRX $8.50
- AVG Volume (30 Days)
- TETE 8.9K
- CMRX 11.2M
- Earning Date
- TETE 01-01-0001
- CMRX 11-07-2024
- Dividend Yield
- TETE N/A
- CMRX N/A
- EPS Growth
- TETE N/A
- CMRX N/A
- EPS
- TETE 0.02
- CMRX N/A
- Revenue
- TETE N/A
- CMRX $159,000.00
- Revenue This Year
- TETE N/A
- CMRX N/A
- Revenue Next Year
- TETE N/A
- CMRX $1,690.28
- P/E Ratio
- TETE $699.42
- CMRX N/A
- Revenue Growth
- TETE N/A
- CMRX N/A
- 52 Week Low
- TETE $11.37
- CMRX $0.75
- 52 Week High
- TETE $12.32
- CMRX $3.39
- Technical
- Relative Strength Index (RSI)
- TETE 68.58
- CMRX 84.35
- Support Level
- TETE $12.21
- CMRX $2.74
- Resistance Level
- TETE $12.32
- CMRX $3.02
- Average True Range (ATR)
- TETE 0.02
- CMRX 0.26
- MACD
- TETE 0.01
- CMRX 0.18
- Stochastic Oscillator
- TETE 84.62
- CMRX 77.13
About TETE Technology & Telecommunication Acquisition Corporation
Technology & Telecommunication Acquisition Corp is a blank check company.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.